Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 22, 2007

Med Discovery and Draximage Combine Techniques

  • Med Discovery and Draximage are collaborating to explore the combination of the former’s targeted protein therapeutics with the latter’s radiopharmaceutical background in the therapeutic and diagnostics field.

    Med Discovery reports that its preclinical candidates are potential therapeutic agents for prostate cancer as well as other cancers. This partnership provides initially for the radiolabeling of certain proteins to assess the enhancement of their action and their capability to detect microtumors.

    The proteins will be produced at Med Discovery in Switzerland and radiolabeled by Draximage in Canada.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »